Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Plasma Aliquots for Ligneous Conjunctivitis
NCT04275232Phase 3Enrolling by invitation
- Start
- May 2025
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in ligneous conjunctivitis. Primary endpoint: Resolution of pseudo membrane associated with ligneous conjunctivitis at 2 years. Started May 2025; status: enrolling by invitation.
02
Conditions
ligneous conjunctivitis
Beyond the preview
Go deeper on NCT04275232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275232.